Background: Disseminated granuloma annulare (DGA) is a benign and usually asymptomatic skin disease. However, many patients feel aesthetically disfigured and ask for treatment. Until today, no standard therapy is recommended. Objective: To evaluate the safety and efficacy of oral vitamin E treatment compared to the natural course of DGA. Methods: This single-centre observational cohort study included 38 consecutive patients with histologically confirmed DGA. 21 patients underwent treatment with oral vitamin E, whereas 17 patients preferred a wait-and-see approach. Results: Complete healing (40%) and improvement (30%) were frequently seen under oral vitamin E therapy. However, DGA also spontaneously disappeared in 31% and improved in 25% of untreated control patients. Vitamin E therapy was very well tolerated. Conclusions: Oral vitamin E treatment is a safe and probably effective therapy for DGA. As the natural course of DGA leads to complete healing or significant improvement in many cases, ‘primum nil nocere' should be the maxim.

Keywords:
Fumaric acid ester, Granulomatous skin disease , Interleukin-1β, Nuclear factor κB, Psoralen plus ultraviolet A, Tumour necrosis factor-α inhibitor
1.
Kowalzick L: Granuloma annulare. Hautarzt 2005;56:1071-1081.
2.
Cyr PR: Diagnosis and management of granuloma annulare. Am Fam Physician 2006;74:1729-1734.
3.
Dabski K, Winkelmann RK: Generalized granuloma annulare: clinical and laboratory findings in 100 patients. J Am Acad Dermatol 1989;20:39-47.
4.
Jain S, Stephens CJ: Successful treatment of disseminated granuloma annulare with topical tacrolimus. Br J Dermatol 2004;150:1042-1043.
5.
Rigopoulos D, Prantsidis A, Christofidou E, Ioannides D, Gregoriou S, Katsambas A: Pimecrolimus 1% cream in the treatment of disseminated granuloma annulare. Br J Dermatol 2005;152:1364-1365.
6.
Cook-Mills JM, McCary CA: Isoforms of vitamin E differentially regulate inflammation. Endocr Metab Immune Disord Drug Targets 2010;10:348-366.
7.
Kaileh M, Sen R: Role of NF-kappaB in the anti-inflammatory effects of tocotrienols. J Am Coll Nutr 2010;29:334-339.
8.
Devaraj S, Jialal I: Alpha-tocopherol decreases interleukin-1 beta release from activated human monocytes by inhibition of 5-lipoxygenase. Arterioscler Thromb Vasc Biol 1999;19:1125-1133.
9.
Smith KJ, Norwood C, Skelton H: Treatment of disseminated granuloma annulare with a 5-lipoxygenase inhibitor and vitamin E. Br J Dermatol 2002;146:667-670.
10.
Goldstein RK, Zillikens D, Miller K, Elsner P, Burg G: Local treatment of disseminated granuloma annulare with a vitamin E emulsion. Hautarzt 1991;42:176-178.
11.
Burg G: Disseminated granuloma annulare: therapy with vitamin E topically. Dermatology 1992;184:308-309.
12.
Studer EM, Calza AM, Saurat JH: Precipitating factors and associated diseases in 84 patients with granuloma annulare: a retrospective study. Dermatology 1996;193:364-368.
13.
Nebesio CL, Lewis C, Chuang TY: Lack of an association between granuloma annulare and type 2 diabetes mellitus. Br J Dermatol 2002;146:122-124.
14.
Eberlein-König B, Mempel M, Stahlecker J, Forer I, Ring J, Abeck D: Disseminated granuloma annulare - treatment with fumaric acid esters. Dermatology 2005;210:223-226.
15.
Kreuter A, Gambichler T, Altmeyer P, Brockmeyer NH: Treatment of disseminated granuloma annulare with fumaric acid esters. BMC Dermatol 2002;2:5.
16.
Weber HO, Borelli C, Röcken M, Schaller M: Treatment of disseminated granuloma annulare with low-dose fumaric acid. Acta Derm Venereol 2009;89:295-298.
17.
Plotner AN, Mutasim DF: Successful treatment of granuloma annulare with methotrexate. Br J Dermatol 2010;163:1123-1124.
18.
Bégon E, Petitjean B, Bachmeyer B: Long-term efficacy of methotrexate in a patient with generalized granuloma annulare. Ann Dermatol Venereol 2013;140:136-137.
19.
Simon M Jr, von den Driesch P: Antimalarials for control of disseminated granuloma annulare in children. J Am Acad Dermatol 1994;31:1064-1065.
20.
Spadino S, Altomare A, Cainelli C, Franchi C, Frigerio E, Garutti C, Taglioni M, Altomare GF: Disseminated granuloma annulare: efficacy of cyclosporine therapy. Int J Immunopathol Pharmacol 2006;19:433-438.
21.
Steiner A, Pehamberger H, Wolff K: Sulfone treatment of granuloma annulare. J Am Acad Dermatol 1985;13:1004-1008.
22.
Czarnecki DB, Gin D: The response of generalized granuloma annulare to dapsone. Acta Derm Venereol 1986;66:82-84.
23.
Potter MN, Yates P, Slade R, Kennedy CT: Agranulocytosis caused by dapsone therapy for granuloma annulare. J Am Acad Dermatol 1989;20:87-88.
24.
Harth W, Richard G: Retinoids in the therapy of granuloma annulare disseminatum. Hautarzt 1993;44:693-698.
25.
Pasmatzi E, Georgiou S, Monastirli A, Tsambaos D: Temporary remission of disseminated granuloma annulare under oral isotretinoin therapy. Int J Dermatol 2005;44:169-171.
26.
Hertl MS, Haendle I, Schuler G, Hertl M: Rapid improvement of recalcitrant disseminated granuloma annulare upon treatment with the tumour necrosis factor-α inhibitor, infliximab. Br J Dermatol 2005;152:552-555.
27.
Murdaca G, Colombo BM, Barabino G, Caiti M, Cagnati P, Puppo F: Anti-tumor necrosis factor-α treatment with infliximab for disseminated granuloma annulare. Am J Clin Dermatol 2010;11:437-439.
28.
Rosmarin D, LaRaia A, Schlauder S, Gottlieb AB: Successful treatment of disseminated granuloma annulare with adalimumab. J Drugs Dermatol 2009;8:169-171.
29.
Shupack J, Siu K: Resolving granuloma annulare with etanercept. Arch Dermatol 2006;142:394-395.
30.
Kreuter A, Altmeyer P, Gambichler T: Failure of etanercept therapy in disseminated granuloma annulare. Arch Dermatol 2006;142:1236-1237.
31.
Voulgari PV, Markatseli TE, Exarchou SA, Zioga A, Drosos AA: Granuloma annulare induced by anti-tumour necrosis factor therapy. Ann Rheum Dis 2008;67:567-570.
32.
Ratnarathorn M, Raychaudhuri SP, Naguwa S: Disseminated granuloma annulare: a cutaneous adverse effect of anti-TNF agents. Indian J Dermatol 2011;56:752-754.
33.
Inui S, Nishida Y, Itami S, Katayama I: Disseminated granuloma annulare responsive to narrowband ultraviolet B therapy. J Am Acad Dermatol 2005;53:533-534.
34.
Browne F, Turner D, Goulden V: Psoralen and ultraviolet A in the treatment of granuloma annulare. Photodermatol Photoimmunol Photomed 2011;27:81-84.
35.
Salomon N, Walchner M, Messer G, Plewig G, Röcken M: Bath-PUVA therapy of granuloma annulare. Hautarzt 1999;50:275-279.
36.
Schnopp C, Tzaneva S, Mempel M, Schulmeister K, Abeck D, Tanew A: UVA1 phototherapy for disseminated granuloma annulare. Photodermatol Photoimmunol Photomed 2005;21:68-71.
37.
Jantke ME, Bertsch HP, Schön MP, Fuchs T: Treatment of disseminated granuloma annulare with anthralin. Hautarzt 2011;62:935-939.
© 2013 S. Karger AG, Basel
2013
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.